Clover Biopharmaceuticals, a global clinical-stage biotech, has completed the enrolment of adult and elderly participants in its SPECTRA study, a global Phase II/III clinical trial examining the safety, efficacy and immunogenicity of the company’s Covid-19 vaccine, SCB-2019. Around 29,000 adults were enrolled in the trial, one of the most ethnically diverse Covid-19 clinical trials to date; over 45% of participants were from Asia, 45% were from Latin America, and the remainder were from Africa and Europe.
Batavia Biosciences and RocketVax, a subsidiary of Switzerland-based start-up Swiss Rockets, have joined forces to work on an investigational Covid-19 vaccine, RVX-13. Batavia said it is collaborating with the company to develop a clinical process capable of delivering 1,000 doses of material for the clinical trials. The vaccine is scheduled to enter Phase I clinical trials in 2022.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The World Health Organization (WHO) has recommended interleukin-6 receptor blockers for treatment of severely or critically ill Covid-19 patients, especially when administered along with corticosteroids. The updated guidelines for patient care are based on a living network meta-analysis initiated by WHO, the largest such analysis of the drugs to date. These are the first drugs found to be effective against Covid-19 since WHO recommended corticosteroids in September 2020. WHO has urged drug makers to reduce prices and make supplies of the drug available to low- and middle-income countries.
